News for Generation Bio Co. (GBIO)

Cash Position: $185.2 million as of December 31, 2024, expected to fund operations into the second half of 2027.Research and Development Expenses: $15.5 millio

Generation Bio (GBIO) delivered earnings and revenue surprises of -14.29% and 6.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[548339]**

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (GBIO), a biotechnology company working to change what's possible for people living wit

Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On December 31, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving Gene

META_DESC_INVESTMENT_IDEA

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on silencing hard-t

**media[507425]**

Generation Bio (GBIO) delivered earnings and revenue surprises of 17.86% and 249.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

EQS-News: BB Biotech AG / Key word(s): Interim Report BB Biotech: Strategic reallocation of portfolio assets progressing ...

**media[443299,443300]**

CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs - WALTHAM, Mass., Sept. ...

Generation Bio Co. (NASDAQ: GBIO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.

Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also…

Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair...

EQS-News: BB BIOTECH AG / Key word: Interim Report BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates...

TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned...

CAMBRIDGE, Mass., Sept. 20, 2022 -- Generation Bio Co. , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip... | September 20, 2022